Crónicas de autores

Viviana Alicia Catania *

Autor invitado por SIIC

El trabajo aporta nuevas evidencias sobre la patogenia de la colestasis inducida por estrógenos

VENTAJAS DE LA EXCRECION SINUSOIDAL DE COMPUESTOS ENDOGENOS Y EXOGENOS EN LA COLESTASIS POR ESTROGENOS

La colestasis por etinilestradiol es de etiología multifactorial. Entre otros efectos ya descritos, observamos que el tratamiento con etinilestradiol aumenta la expresión y actividad de Mrp3 (un transportador sinusoidal) en hígado, lo que favorece la excreción de sus sustratos hacia el plasma, evitando su acumulación intracelular y el daño consiguiente.

*Viviana Alicia Catania
describe para SIIC los aspectos relevantes de su trabajo
ETHYNYLESTRADIOL INCREASES EXPRESSION AND ACTIVITY OF RAT LIVER MRP3
Drug Metabolism and Disposition,
34(6):1030-1034 Jun, 2006

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Instituto de Fisiología Experimental (IFISE-CONICET), Rosario, Argentina
Imprimir nota
Referencias bibliográficas
1. Schreiber AJ, Simon FR. Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology 1983; 3:607-613.
2. Vore M. Estogen cholestasis. Membranes, metabolites, or receptors? Gastoenterology 1987; 93:643-649.
3. Simon FR, Fortune J, Iwashashi M, Gartung C, Wolkoff A, Sutherland E. Ethinylestradiol cholestasis involves alterations in expression of liver sinusoidal transporters. Am J Physiol 1996; 271:G1043-1052.
4. Davis RA, Kern FJr. Effects of ethinylestradiol and phenobarbital on bile acid synthesis and biliary bile acid and cholesterol excretion. Gastroenterology 1976; 70:1130-1135.
5. Bossard R, Stieger B, O'Neill B, Fricker G, Meier PJ. Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest 1993; 91:2714-2720.
6. Koopen NR, Post SM, Wolters H, Havinga R, Stellaard F, Boverhof R, Kuipers F, Princen HM. Differential effects of 17-ethinylestradiol on the neutral and acidic pathways of bile salt synthesis in the rat. J Lipid Res 1999; 40:100-108.
7. Keppler D, König J, Buchler M. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv Enzyme Regul 1997; 37:321-333.
8. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL. The rat canalicular conjugate export pump (mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113:255-264.
9. Crocenzi FA, Sánchez Pozzi EJ, Pellegrino JM, Favre CO, Rodríguez Garay EA, Mottino AD, Coleman R, Roma MG. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat:a study in vivo and in isolated hepatocyte couplets. Hepatology 2001; 34:329-339.
10. Koopen NR, Wolters H, Havinga R, Vonk RJ, Jansen PLM, Müller M, Kuipers F. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 1998; 27:537-545.
11. Hirohashi T, Ito K, Ogawa K, Suzuki H, Kume K, Shimizu T, Sugiyama Y. Hepatic expression of multidrug resistance-associated protein (MRP)-like proteins maintained in Eisai hyperbilirubinemic rats (EHBR). Mol Pharmacol 1998; 53:1068-1075.
12. Johnson BM, Zhang P, Schuetz JD, Brouwer KL. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp2) 2-deficient rats. Drug Metab Dispos 2005; 34:556-562.
13. Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001; 34:351-359.
14. Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001; 33:783-791.
15. König J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999; 29:1156-1163.
16. Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, Chen Z-S, Grinberg A, Westphal H, Klein-Szanto A, Lerro A, Kruh GD. Analysis of the in vivo functions of Mrp3. Mol Pharmacol 2005; 68:160-168.
17. Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 2000; 278:G438-G446.
18. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2 and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 2002; 300:97-104.
19. Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, Brouwer KL. Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment of phenobarbital pretreatment. Drug Metab Dispos 2002; 30:962-969.
20. Ghanem CI, Ruiz ML, Villanueva SSM, Luquita MG, Catania VA, Jones B, Bengochea LA, Vore M, Mottino AD. Shift from biliary to urinary elimination of acetaminophen-glucuronide in acetaminophen-pretreated rats. J Pharmacol Exp Ther 2005; 315:987-995.
21. Akita H, Suzuki H, Sugiyama Y. Sinusoidal efflux of taurocholate correlates with the hepatic expression level of Mrp3. Biochem Biophys Res Commun 2002; 299:681-687.
22. Slitt AL, Cherrington NJ, Naher JM, Klaassen KD. Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab Dispos 2003; 31:1176-1186.
23. Kamisako T, Ogawa H. Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis. J Gastroenterol Hepatol 2005; 20:1429-1434.
24. Kessler FK, Kessler MR, Auyeung DJ, Ritter JK. Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyltransferases. Drug Metab Dispos 2002; 30:324-330.
25. Catania VA, Luquita MG, Sánchez Pozzi EJ, Ikushiro S, Emi Y, Iyanagi T, Mottino AD. Effect of spironolactone on the expression of rat hepatic UDP-glucuronosyltransferase. Biochem Pharmacol 2003; 66:171-177.
Otros artículos de Viviana Alicia Catania

Catania VA, Luquita MG, Sánchez Pozzi EJ, Mottino AD. Enhancement of intestinal UDP-glucuronosyltransferase activity in partially hepatectomized rats. Biochem Biophys Acta 1998; 1380:345-353.
Luquita MG, Catania VA, Sánchez Pozzi EJ, Veggi LM, Hoffman T, Pellegrino JM, Ikushiro S, Emi Y, Iyanagi T, Vore M, Mottino AD. Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. J Pharm Exp Ther 2001; 298:49-56.
Catania VA, Luquita MG, Sánchez Pozzi EJ, Ikushiro S, Emi Y, Iyanagi T, Mottino AD. Effect of spironolactone on the expression of rat hepatic UDP-glucuronosyltransferase. Biochem Pharmacol 2003; 66:171-177.
Catania VA, Sánchez Pozzi EJ, Luquita MG, Ruiz ML, Villanueva SSM, Jones B, Mottino AD. Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein 2. Annals of Hepatology 2004; 3:11-17.
Villanueva SSM, Ruiz ML, Luquita MG, Sánchez Pozzi EJ, Catania VA, Mottino AD. Involvement of Mrp2 in hepatic and intestinal disposition of dinitrophenyl-S-glutathione in partially hepatectomized rats. Toxicol Sci 2005; 84:4-11.
Ruiz ML, Villanueva SSM, Luquita MG, Sánchez Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD, Catania VA. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem Pharmacol 2005; 69:531-539.
Crocenzi FA, D'Andrea V, Catania VA, Luquita MG, Pellegrino JM, Ochoa JE, Mottino AD, Sánchez Pozzi EJ. Prevention of Mrp2 activity impairment in ethinyltestradiol-induced cholestasis by ursodeoxycholate in the rat. Drug Metab Disposition 2005; 33:888-891.
Ghanem CI, Ruiz ML, Villanueva SSM, Luquita MG, Catania VA, Jones B, Bengochea LA, Vore M, Mottino AD. Shift from biliary to urinary elimination of acetaminophen glucuronide in acetaminophen pretreated rats. J Pharmacol Exp Ther 2005; 315:987-995.
Ruiz ML, Villanueva SSM, Luquita MG, Vore M, Mottino AD, Catania VA. Ethynylestradiol increases expression and activity of rat liver Mrp3. Drug Metab Dispos 2006; 34:1030-1034.
Villanueva SSM, Ruiz ML, Soroka CJ, Cai SY, Luquita MG, Torres AM, Sánchez Pozzi EJ, Pellegrino JM, Boyer JL, Catania VA, Mottino AD. Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct ligated rats. Drug Metab Dispos 2006; 34:1301-1309.

Para comunicarse con Viviana Alicia Catania mencionar a SIIC como referencia:
vcatania@fbioyf.unr.edu.ar

Autor invitado
12 de julio, 2006
Descripción aprobada
29 de septiembre, 2006
Reedición siicsalud
7 de junio, 2021

Acerca del trabajo completo
VENTAJAS DE LA EXCRECION SINUSOIDAL DE COMPUESTOS ENDOGENOS Y EXOGENOS EN LA COLESTASIS POR ESTROGENOS



Autor
Viviana Alicia Catania1, María Laura Ruiz2, Silvina Stella Maris Villanueva3, Marcelo Gabriel Luquita4, Mary Vore5, Aldo Domingo Mottino6
1, Instituto de Fisiología Experimental (IFISE-CONICET), Rosario, Argentina
2, Instituto de Fisiología Experimental (IFISE-CONICET), Argentina, Becaria Doctoral de CONICET
3, Instituto de Fisiología Experimental (IFISE-CONICET), Argentina, Becaria Doctoral de CONICET
4, Instituto de Fisiología Experimental (IFISE-CONICET), Argentina, Profesional Adjunto de CONICET
5, Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky, USA, Lexington, EE.UU., Professor-Director
6, Instituto de Fisiología Experimental (IFISE-CONICET), Argentina, Investigador Principal de CONICET

Acceso a la fuente original
Drug Metabolism and Disposition
http://dmd.aspetjournals.org/

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades
    


ua40317